gregarious 发表于 2025-3-25 05:57:23
http://reply.papertrans.cn/67/6697/669653/669653_21.pngsurrogate 发表于 2025-3-25 10:06:17
Rodent Models for ASD Biomarker Development biochemical, anatomical, and electrophysiological measures are emerging as potential disease-relevant biomarkers that could inform the diagnosis and clinical management of ASD. Rodent ASD models play a key role in ASD research as essential experimental tools. Nevertheless, there are challenges andMorose 发表于 2025-3-25 11:41:09
http://reply.papertrans.cn/67/6697/669653/669653_23.pngSTING 发表于 2025-3-25 16:13:23
Functional Connectivity Biomarkers in Schizophreniapite over 100 years of study, the treatment for schizophrenia remains limited, partially due to the lack of knowledge about the neural mechanisms of the illness and how they relate to symptoms. The US Food and Drug Administration (FDA) and the National Institute of Health (NIH) have provided seven bANTE 发表于 2025-3-25 20:51:29
http://reply.papertrans.cn/67/6697/669653/669653_25.pngjeopardize 发表于 2025-3-26 02:11:47
http://reply.papertrans.cn/67/6697/669653/669653_26.pngCANE 发表于 2025-3-26 08:17:36
http://reply.papertrans.cn/67/6697/669653/669653_27.pnghardheaded 发表于 2025-3-26 10:08:17
http://reply.papertrans.cn/67/6697/669653/669653_28.pngfaucet 发表于 2025-3-26 15:19:26
Mismatch Negativity (MMN) as a Pharmacodynamic/Response Biomarker for NMDA Receptor and Excitatory/Irments associated with schizophrenia (CIAS) are key features of the disorder and primary predictors of long-term disability. At the neurochemical level, both CIAS and negative symptoms are potentially attributable to dysfunction or dysregulation of N-methyl-.-aspartate receptor (NMDAR)-mediated neurAGGER 发表于 2025-3-26 18:29:32
http://reply.papertrans.cn/67/6697/669653/669653_30.png